Sep 15, 2014 7:40 AM

Gilead to license generic version of Sovaldi

The Associated Press

Gilead Sciences says it has reached a deal with several generic drugmakers to produce cheaper versions of its popular, expensive hepatitis C drug Sovaldi for use in developing countries.

Gilead says the India-based drugmakers will make a generic version of Sovaldi, also known as sofosbuvir, and another investigational drug for distribution in 91 countries.

Sovaldi hit the U.S. market late last year, and Gilead has taken criticism over the $1,000-per-pill price attached to the drug, which has been hailed as a breakthrough treatment. A full course of treatment can cost $84,000.

Gilead Sciences Inc. did not detail the price on the generic version of Sovaldi. The Indian companies will receive a technology transfer that helps them start production quickly. They also will pay sales royalties to Gilead.


--  Dealing with the Disease of Addiction? Click here for help --

More from

NH1 News Debates
NH1 News Replay

NH1 on Twitter

NH1 SkyView Cameras

NH1 on Facebook

Check out NH1 News Rail Polls on LockerDome on LockerDome